Eli Lilly’s $20.9 Billion M&A Spree Signals a Strategic Pivot Ahead of a Pivotal Earnings Report
Published on 04/30/2026 at 04:42 | Redaktion boerse-global.de
When Eli Lilly reports first-quarter results today, the numbers will tell only part of the story. The pharmaceutical giant is navigating a rare moment of tension: booming sales volumes in its GLP-1 franchise are colliding with shrinking margins, while a newly launched oral obesity drug struggles to gain traction against a rival that beat it to market by months.
Wall Street expects revenue to climb roughly 37% year-over-year to around $19.3 billion — impressive by any standard, yet a deceleration from the 45% growth posted in the same quarter last year. Earnings per share are forecast at approximately $34.25, with the full-year revenue target set at $81.5 billion. Analysts have been revising estimates upward in recent weeks, though the bar is high after last year’s blistering pace.
Foundayo’s Rocky Debut
The April 1 FDA approval of Foundayo (orforglipron) — the first oral GLP-1 pill free of food or fluid restrictions — was supposed to be a milestone. Instead, early prescription data from IQVIA and Citi show the drug trailing Novo Nordisk’s oral Wegovy, which launched in December 2025. That head start of several months has given Novo a critical advantage at pharmacy counters.
The Baron Health Care Fund flagged two concerns in its first-quarter investor letter: fears of a pricing war in the obesity segment and the risk that oral formulations could cannibalize Lilly’s existing injectable business, Zepbound. The market has already priced in some of that skepticism. Shares have fallen roughly 21% since the start of the year, trading near 730 euros — more than 23% below the 52-week high of 959.50 euros.
Should investors sell immediately? Or is it worth buying Eli Lilly?
For patients with private insurance, co-pays for Foundayo start at $25 per month; cash payers will pay $149. A temporary CMS bridge program will make the drug available through Medicare starting in July 2026, alongside Zepbound and Wegovy. But Leerink Partners warns that Novo’s oral version could limit Foundayo’s uptake in the U.S., prompting the firm to cut its 2027 earnings estimate for Lilly.
A $20.9 Billion Pivot to Oncology
While Foundayo grabs headlines, Lilly has been quietly reshaping its portfolio through an unprecedented acquisition spree. In the first four months of 2026, the company spent roughly $20.9 billion on M&A — more than in any full year of the past decade. The targets are concentrated in oncology and genetic engineering, pushing Lilly deeper into hematology and DNA editing.
Leerink analysts view this as a deliberate strategy: reinvesting the massive cash flows from GLP-1 sales into long-term pipeline diversification. The move reduces Lilly’s dependence on the weight-loss and diabetes market, where pricing pressures are intensifying. List prices for GLP-1 drugs have fallen from over $1,000 per month to between $300 and $350, squeezing gross margins.
Clinical Data Offers a Counterpoint
Despite the slow commercial start, Foundayo’s clinical profile remains compelling. In the Achieve-4 study, orforglipron demonstrated a 16% lower risk of major adverse cardiovascular events compared to insulin glargine in patients with type 2 diabetes and elevated cardiac risk. The drug met all primary endpoints for weight reduction and glycemic control over 104 weeks. Lilly plans to file for a type 2 diabetes indication by the end of the second quarter.
Morgan Stanley maintains a price target of $1,327, citing the potential from Medicare expansion, though recent comments from UnitedHealth and CVS have raised questions about the pace of coverage under the CMS BALANCE program starting in 2027. Bernstein SocGen Group reaffirmed its outperform rating with a $1,300 target, expecting Lilly to beat Q1 estimates and possibly raise its full-year guidance.
Eli Lilly at a turning point? This analysis reveals what investors need to know now.
What to Watch on the Call
Today’s analyst conference will be the main event. Foundayo sales won’t appear in the Q1 report — the launch fell outside the reporting period — so investors will focus on management’s commentary about production ramp-up, pricing strategy, and the impact of tariffs on the broader pharmaceutical sector. The company is also investing billions in U.S. manufacturing capacity, including new plants in Texas and Virginia.
Morningstar rates the stock three out of five stars, with a fair value estimate of $870 — raised after strong 2025 results but not signaling undervaluation. With the stock sitting roughly 24% below its 52-week high, the earnings call could determine whether the selloff was an overreaction or the beginning of a longer reset.
Ad
Eli Lilly Stock: New Analysis - 30 April
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
